A Phase 2 interventional study of CD5024 1% cream and CD5024 cream placebo in Acne, sponsored by Galderma R&D. Completed at 7 sites in 3 countries. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2020-12-11.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Acne Vulgaris by Galderma Group AG — none open to participants now, 1 under way, 1 of them phase 3. Acne Vulgaris · Galderma Group AG.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 35th largest by enrollment of the 46 interventional ones that give a count, is one of 4 that started in 2016, is one of 5 in phase 2, and was the 44th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 49 studies in Acne Vulgaris by Galderma Group AG is open now. The open studies under Acne Vulgaris, anywhere →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 70 is close to the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 194 across the 46 interventional studies, 3,113 across the 3 observational. Of the 48 that completed or were terminated, 39 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
1 of the studies in Acne Vulgaris by Galderma Group AG that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186413Phase 3Galderma R&DA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Exploratory, multi-center, randomised, investigator-blinded, vehicle controlled study using intra-individual comparison involving subjects with acne vulgaris on face to evaluate the efficacy of CD5024 1% cream over a 6-week treatment period compared to its vehicle.
Study drugs application will be performed once daily, 5 days a week during 6 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject has a medical diagnosis of acne vulgaris :
2.1 at least 20 (twenty) inflammatory lesions and a maximum of 100 (one hundred) non-inflammatory lesions (nose is excluded for the lesion count) at Baseline
2.2 symmetry of the lesions: No more than twice as many acne lesions on one side as compared to the other side at Baseline
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active drug;
Drug: CD5024 1% cream
Placebo of active drug;
Drug: CD5024 cream placebo
Positive control;
Drug: CD0271/CD1579 gel
Placebo of positive control;
Drug: CD0271/CD1579 gel placebo
500 µL on half-face, five days a week during 6 weeks
500 µL on half-face, five days a week during 6 weeks
500 µL on half-face, five days a week during 6 weeks
500 µL on half-face, five days a week during 6 weeks
Inflammatory Lesion Count (Papules and Pustules) at Day 40
Inflammatory lesion count corresponded to the sum of papules and pustules.
Time frame: Day 40
Inflammatory Lesion Count (Papules and Pustules) at Baseline (Day 1)
Inflammatory lesion count corresponded to the sum of papules and pustules.
Time frame: Baseline (Day 1)
Percent Reduction From Baseline (Day 1) in Inflammatory Lesion Count at Day 40
Inflammatory lesion count corresponded to the sum of papules and pustules.
Time frame: Baseline (Day 1), and Day 40
Total Lesion Count at Baseline (Day 1) and Day 40
Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules.
Time frame: Baseline (Day 1), and Day 40
Percent Reduction From Baseline (Day 1) in Total Lesions at Day 40
Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules.
Time frame: Baseline (Day 1), and Day 40
Non-Inflammatory Lesion Count at Baseline (Day 1) and Day 40
Non-inflammatory lesion counts corresponded to the sum of open and closed comedones.
Time frame: Baseline (Day 1), and Day 40
Percent Reduction From Baseline in Non-Inflammatory Lesion at Day 40
Non-inflammatory lesion counts corresponded to the sum of open and closed comedones.
Time frame: Baseline (Day 1), and Day 40
Number of Participants Reported for Investigator's Preference on a 5-Point Scale at Day 40
The Investigator gave opinion on their preference after comparison of the left and right sides of the face using the 5-point scale ranging from -2 to 2. The score and description indicated as follows: -2= left side of the face much better than right side, -1= left side of the face better than right side, 0= no clinical difference between the right and left sides of the face, 1= right side of the face better than the left side, 2= right side of the face much better than the left side.
Time frame: Day 40
Number of Participants Reported for Participant's Preference on 5-Point Scale at Day 40
The participants gave opinion on their preference after comparison of the left and right sides of the face using the 5-point scale ranging from -2 to 2. The score and description indicated as follows: -2= left side of the face much better than right side, -1= left side of the face better than right side, 0= no clinical difference between the right and left sides of the face, 1= right side of the face better than the left side, 2= right side of the face much better than the left side.
Time frame: Day 40
Number of Participants With Adverse Events (AEs)
AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily had a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Time frame: From start of study up to follow up (Week 7)
Number of Participants Reported Worst Local Tolerability Score on Treated Areas (Face and Ear) From Day 1 to Follow up (Week 7)
Signs and symptoms of local cutaneous irritation(local tolerability \[erythema, scaling, dryness, stinging/burning, pruritus\]) were evaluated on all treated areas (face and behind ears if applicable) every day from Day 1 up to follow-up (Week 7) using a 4-point scale of None (0), Mild (1), Moderate (2), or Severe (3). Number of participants reported worst local tolerability score on treated areas from Day 1 to follow up (Week 7) was reported.
Time frame: From Day 1 up Follow up (Week 7)
This study was conducted at six centers in three countries (Germany, France, Canada) between 25 April 2016 (first participant screened) to 02 November 2016 (last participant completed).
| Milestone | Group I: CD5024 Cream Versus Its Vehicle | Group II: Epiduo Gel Versus Its Vehicle |
|---|---|---|
| Started | 48 | 22 |
| Completed | 45 | 19 |
| Not completed | 3 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Personal reasons | 1 | 0 |
Inflammatory lesion count corresponded to the sum of papules and pustules.
| lesion count | CD5024 1% Cream | CD5024 1% Cream Matched Placebo | Adapalene Benzoyl Peroxyde | Adapalene Benzoyl Peroxyde Matched Placebo |
|---|---|---|---|---|
| Inflammatory Lesion Count (Papules and Pustules) at Day 40 | 10.1 ± 5.8 | 8.9 ± 5.0 | 6.1 ± 4.9 | 9.4 ± 5.7 |
Inflammatory lesion count corresponded to the sum of papules and pustules.
| lesion count | CD5024 1% Cream | CD5024 1% Cream Matched Placebo | Adapalene Benzoyl Peroxyde | Adapalene Benzoyl Peroxyde Matched Placebo |
|---|---|---|---|---|
| Inflammatory Lesion Count (Papules and Pustules) at Baseline (Day 1) | 16.5 ± 4.9 | 17.5 ± 7.4 | 17.6 ± 8.6 | 16.6 ± 7.2 |
Inflammatory lesion count corresponded to the sum of papules and pustules.
| percent reduction of lesion count | CD5024 1% Cream | CD5024 1% Cream Matched Placebo | Adapalene Benzoyl Peroxyde | Adapalene Benzoyl Peroxyde Matched Placebo |
|---|---|---|---|---|
| Percent Reduction From Baseline (Day 1) in Inflammatory Lesion Count at Day 40 | 35.7 ± 43.4 | 44.4 ± 32.3 | 65.5 ± 24.0 | 42.5 ± 30.1 |
Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules.
| lesion count | CD5024 1% Cream | CD5024 1% Cream Matched Placebo | Adapalene Benzoyl Peroxyde | Adapalene Benzoyl Peroxyde Matched Placebo |
|---|---|---|---|---|
| Baseline (Day 1) | 37.7 ± 11.2 | 39.4 ± 13.7 | 37.3 ± 20.2 | 36.4 ± 18.0 |
| Day 40 | 26.4 ± 16.8 | 25.9 ± 14.3 | 19.3 ± 15.0 | 25.5 ± 17.2 |
Total lesion counts corresponded to the sum of inflammatory and non-inflammatory lesions, and papules.
| percent reduction in total lesion count | CD5024 1% Cream | CD5024 1% Cream Matched Placebo | Adapalene Benzoyl Peroxyde | Adapalene Benzoyl Peroxyde Matched Placebo |
|---|---|---|---|---|
| Percent Reduction From Baseline (Day 1) in Total Lesions at Day 40 | 32.5 ± 32.2 | 34.0 ± 27.1 | 50.2 ± 27.2 | 27.8 ± 31.8 |
Non-inflammatory lesion counts corresponded to the sum of open and closed comedones.
| lesion count | CD5024 1% Cream | CD5024 1% Cream Matched Placebo | Adapalene Benzoyl Peroxyde | Adapalene Benzoyl Peroxyde Matched Placebo |
|---|---|---|---|---|
| Baseline (Day 1) | 21.1 ± 9.5 | 21.8 ± 10.7 | 19.6 ± 14.1 | 19.6 ± 13.6 |
| Day 40 | 16.2 ± 13.1 | 16.9 ± 12.7 | 13.0 ± 12.0 | 16.0 ± 14.1 |
Non-inflammatory lesion counts corresponded to the sum of open and closed comedones.
| percent reduction of lesion count | CD5024 1% Cream | CD5024 1% Cream Matched Placebo | Adapalene Benzoyl Peroxyde | Adapalene Benzoyl Peroxyde Matched Placebo |
|---|---|---|---|---|
| Percent Reduction From Baseline in Non-Inflammatory Lesion at Day 40 | 27.8 ± 39.4 | 21.3 ± 42.0 | 36.9 ± 36.1 | 11.7 ± 48.6 |
The Investigator gave opinion on their preference after comparison of the left and right sides of the face using the 5-point scale ranging from -2 to 2. The score and description indicated as follows: -2= left side of the face much better than right side, -1= left side of the face better than right side, 0= no clinical difference between the right and left sides of the face, 1= right side of the face better than the left side, 2= right side of the face much better than the left side.
| Participants | Group I: CD5024 Cream Versus Its Vehicle | Group II: Epiduo Gel Versus Its Vehicle |
|---|---|---|
| Day 40 (Active much better than Vehicle) | 0 | 4 |
| Day 40 (Active better than Vehicle) | 16 | 7 |
| Day 40 (No clinical difference between Active and Vehicle) | 16 | 6 |
| Day 40 (Vehicle better than Active) | 14 | 4 |
| Day 40 (Vehicle much better than Active) | 1 | 0 |
The participants gave opinion on their preference after comparison of the left and right sides of the face using the 5-point scale ranging from -2 to 2. The score and description indicated as follows: -2= left side of the face much better than right side, -1= left side of the face better than right side, 0= no clinical difference between the right and left sides of the face, 1= right side of the face better than the left side, 2= right side of the face much better than the left side.
| Participants | Group I: CD5024 Cream Versus Its Vehicle | Group II: Epiduo Gel Versus Its Vehicle |
|---|---|---|
| Day 40 (Active much better than Vehicle) | 2 | 2 |
| Day 40 (Active better than Vehicle) | 11 | 11 |
| Day 40 (No clinical difference between Active and Vehicle) | 15 | 4 |
| Day 40 (Vehicle better than Active) | 16 | 3 |
| Day 40 (Vehicle much better than Active) | 3 | 1 |
AE was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily had a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
| Participants | Group I: CD5024 Cream Versus Its Vehicle | Group II: Epiduo Gel Versus Its Vehicle |
|---|---|---|
| Number of Participants With Adverse Events (AEs) | 32 | 14 |
Signs and symptoms of local cutaneous irritation(local tolerability \[erythema, scaling, dryness, stinging/burning, pruritus\]) were evaluated on all treated areas (face and behind ears if applicable) every day from Day 1 up to follow-up (Week 7) using a 4-point scale of None (0), Mild (1), Moderate (2), or Severe (3). Number of participants reported worst local tolerability score on treated areas from Day 1 to follow up (Week 7) was reported.
| Participants | CD5024 1% Cream | CD5024 1% Cream Matched Placebo | Adapalene Benzoyl Peroxyde | Adapalene Benzoyl Peroxyde Matched Placebo |
|---|---|---|---|---|
| Face: Erythema: 0-None | 37 | 38 | 8 | 15 |
| Face: Erythema: 1-Mild | 9 | 9 | 11 | 6 |
| Face: Erythema: 2-Moderate | 2 | 1 | 3 | 1 |
| Face: Scaling/Desquamation: 0-None | 38 | 38 | 5 | 16 |
| Face: Scaling/Desquamation: 1-Mild | 10 | 10 | 13 | 5 |
| Face: Scaling/Desquamation: 2- Moderate | 0 | 0 | 4 | 1 |
| Face: Dryness: 0-None | 38 | 37 | 4 | 10 |
| Face: Dryness: 1-Mild | 10 | 11 | 13 | 12 |
| Face: Dryness: 2-Moderate | 0 | 0 | 5 | 0 |
| Face: Stinging/Burning: 0-None | 44 | 43 | 8 | 17 |
| Face: Stinging/Burning: 1-Mild | 3 | 4 | 8 | 5 |
| Face: Stinging/Burning: 2-Moderate | 1 | 1 | 6 | 0 |
| Ear: Erythema: 0-None | 20 | 20 | 8 | 11 |
| Ear: Erythema: 1-Mild | 2 | 2 | 2 | 0 |
| Ear: Erythema: 2-Moderate | 0 | 0 | 1 | 0 |
| Ear: Scaling/Desquamation: 0-None | 22 | 22 | 7 | 11 |
| Ear: Scaling/Desquamation: 1-Mild | 0 | 0 | 3 | 0 |
| Ear: Scaling/Desquamation: 2-Moderate | 0 | 0 | 1 | 0 |
| Ear: Dryness: 0-None | 22 | 22 | 7 | 10 |
| Ear: Dryness: 1-Mild | 0 | 0 | 3 | 1 |
| Ear: Dryness: 2-Moderate | 0 | 0 | 1 | 0 |
| Ear: Stinging/Burning: 0-None | 22 | 22 | 8 | 11 |
| Ear: Stinging/Burning: 1-Mild | 0 | 0 | 2 | 0 |
| Ear: Stinging/Burning: 2-Moderate | 0 | 0 | 1 | 0 |
Collected over From start of study up to follow up (Week 7). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group I: CD5024 Cream Versus Its Vehicle | 0/48 (0%) | 0/48 (0%) | 32/48 (66.7%) |
| Group II: Epiduo Gel Versus Its Vehicle | 0/22 (0%) | 0/22 (0%) | 11/22 (50%) |
| Event | Group I: CD5024 Cream Versus Its Vehicle | Group II: Epiduo Gel Versus Its Vehicle |
|---|---|---|
| NasopharyngitisInfections and infestations | 14/48 | 4/22 |
| HeadacheNervous system disorders | 13/48 | 5/22 |
| PruritusSkin and subcutaneous tissue disorders | 0/48 | 2/22 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/48 | 0/22 |
| Abdominal painGastrointestinal disorders | 3/48 | 0/22 |
| Age, Continuous(Years) | Group I: CD5024 Cream Versus Its Vehicle | Group II: Epiduo Gel Versus Its Vehicle | Total |
|---|---|---|---|
| Mean | 23.3 ± 4.7 | 23.4 ± 4.4 | 23.3 ± 4.6 |
| Sex: Female, Male(Participants) | Group I: CD5024 Cream Versus Its Vehicle | Group II: Epiduo Gel Versus Its Vehicle | Total |
|---|---|---|---|
| Female | 34 | 14 | 48 |
| Male | 14 | 8 | 22 |
| Race (NIH/OMB)(Participants) | Group I: CD5024 Cream Versus Its Vehicle | Group II: Epiduo Gel Versus Its Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 6 |
| White | 46 | 14 | 60 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Number of inflammatory lesions(Lesion Count) | Group I: CD5024 Cream Versus Its Vehicle | Group II: Epiduo Gel Versus Its Vehicle | Total |
|---|---|---|---|
| Mean | 34.0 ± 11.6 | 34.2 ± 15.1 | 34.0 ± 12.7 |
Ran from Apr 2016 to primary completion in Nov 2016, 6 months.
Results were first posted in Dec 2020, 4 years 1 month after primary completion.
Of 29 industry-sponsored phase 2 interventional studies under Acne Vulgaris, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 6 months is below that.
Counting every sponsor, half of 37 studies reached it within 9 months; a quarter within 6 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivermectin